2023 Nobel Prize in Physiology or Medicine
Reason for Award
for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19
Laureates
Hungary, 
United States of America
United States of America
Explanation
Vaccines work like a protective spell that keeps us from getting sick. Dr. Karikó and Dr. Weissman discovered how to send a tiny instruction sheet called “mRNA” into our bodies so that it works safely. By gently changing a few of the mRNA letters, our bodies don’t panic or get a fever but can still read the message. The message tells cells to make the coronavirus “spike protein,” which acts like a practice target for the immune system. When the real virus shows up, our defenses are ready and we don’t get seriously ill. Thanks to their idea, a brand-new kind of vaccine could be made very quickly and protect people all over the world.
Related Keywords
mRNA vaccine
An mRNA vaccine delivers the genetic blueprint for an antigen directly into the body so host cells themselves produce the target protein and trigger immunity. Because no live or cultured virus is required, only the nucleotide sequence needs to be swapped to address a new pathogen, enabling rapid design. Manufacturing relies on scalable in vitro transcription and purification chemistry instead of cell culture. First authorized during the COVID-19 pandemic in 2020, the platform demonstrated high efficacy and unprecedented speed. It is now being extended to influenza, RSV, and diverse cancer immunotherapies.
nucleoside base modification
Base modification involves replacing uridine, cytidine, or other canonical RNA nucleosides with analogs such as ψ, m1ψ, or m5C. These alterations make the transcript less recognizable to innate sensors, suppressing activation of TLR7/8 and PKR. Reduced cytokine release permits higher mRNA doses without excessive reactogenicity. Simultaneously, modified bases enhance ribosome binding, boosting protein yield. The concept, proven by Karikó and Weissman, is now a cornerstone of clinical mRNA therapeutics.
innate immune evasion
The body detects foreign RNA via TLRs and RIG-I-like receptors, launching interferon responses. Excessive activation hampers translation and causes side effects, so evasion strategies are crucial for mRNA medicines. Beyond base modification, optimized 5' capping and removal of dsRNA by-products further dampen sensing. These measures enable strong antigen presentation and antibody induction while minimizing inflammation. Properly engineered transcripts are treated almost like self-RNA, yielding efficient and safe protein expression.
lipid nanoparticle (LNP)
LNPs are 50–100 nm lipid capsules composed of ionizable lipids, cholesterol, phospholipids and PEG-lipids. They electrostatically encapsulate mRNA at low pH yet become neutral at physiological pH, limiting toxicity. After endocytic uptake, the ionizable lipids destabilize the endosomal membrane and release mRNA into the cytosol. By tweaking lipid composition, researchers can tune organ targeting and innate activation; similar carriers deliver siRNA drugs. Microfluidic manufacturing enables scalable production that powered global vaccine rollout.
Toll-like receptor (TLR)
TLRs are pattern-recognition receptors that initiate inflammation upon sensing viral RNA or bacterial DNA. TLR7 and TLR8 preferentially bind uridine-rich single-stranded RNA, driving production of IFN-α and TNF-α. In mRNA vaccines, excessive TLR activation can cause side effects and inhibit translation, so base modification is used to dampen it. Conversely, moderate TLR signaling supplies adjuvant activity that boosts immunity. Fine-tuning TLR engagement is thus a key design variable for mRNA therapeutics.
translation efficiency
Translation efficiency denotes how rapidly a cytosolic mRNA is converted into protein. It can be maximized by Cap1 capping, an extended poly(A) tail, optimized 5' and 3' UTRs, and nucleoside modifications. Higher efficiency lowers the dose required and reduces side effects. For vaccines, quick synthesis of ample antigen is critical for robust immune memory. Karikó’s group showed that modified bases directly increase ribosome occupancy, thereby boosting translation.
spike protein
The SARS-CoV-2 spike glycoprotein binds the human ACE2 receptor and initiates infection. It is the principal target of neutralizing antibodies, so vaccines present it in a stabilized prefusion form. mRNA vaccines achieve this by introducing two proline substitutions (the 2P mutation) that lock the structure for optimal immune recognition, a strategy borrowed from MERS and RSV structural studies. Spike mutations influence immune escape and transmissibility, hence variant tracking and vaccine updates remain ongoing.
immunogenicity
Immunogenicity denotes how strongly a vaccine provokes antibody and T-cell responses. It depends on the mRNA dose, translation efficiency, and inherent or added adjuvant activity. Excessive dampening of innate signals with modified bases can reduce antibody titers, so LNP composition or dose adjustments may be required. Phase III trials showed that high neutralizing titers and TH1-biased T-cells correlate with protection against severe COVID-19. Evaluation uses neutralization assays, ELISA, and ELISpot, among others.
PKR
Protein kinase R senses double-stranded RNA and phosphorylates eIF2α, halting translation as an antiviral defense. Unmodified mRNA contains secondary structures and dsRNA fragments that activate PKR, undermining vaccine potency. Base modification and HPLC purification greatly reduce PKR engagement and enable high protein expression. PKR links to stress-granule formation and inflammasome activity, thus influencing reactogenicity. Measuring PKR activation is therefore a quality metric for mRNA drug development.
epidemiological impact
Since 2021, billions of mRNA vaccine doses have been administered, sharply reducing COVID-19 hospitalizations and deaths worldwide. Beyond high efficacy, the platform’s speed in manufacturing and updating formulations proved crucial as new variants emerged. Modeling studies estimate millions of lives saved. Booster strategies have been tailored to coverage levels and variant characteristics, with real-world data guiding policy. The success story is reshaping frameworks for future pandemic preparedness.